Hadi Falahatpisheh, DVM, PhD, DABT

Dr. Falahatpisheh has served as our Vice President, Preclinical Development since July 2022. Prior to joining us, he was with Biosplice Therapeutics, where he served as Vice President, Translational Sciences, since November 2020. In 2017, he was a Senior Director at AbbVie/Stemcentrx where he served on the Oncology Leadership Team and led a Preclinical Development Team to support the transition of oncology assets from early discovery to clinical proof of concept. From 2010 to 2017, Dr. Falahatpisheh was at Pfizer as an Associate Research Fellow and Early Oncology Safety Therapeutic Lead, leading early nonclinical activities of anti-cancer targeted modalities. From 2004 to 2010, he served as project toxicologist in multiple therapeutic areas at Merck. Dr. Falahatpisheh received his DVM from Shiraz University, Iran, and his PhD in Molecular Toxicology from Texas A&M. He completed his post-doctoral training in Molecular Biology at the University of Louisville and is certified by the American Board of Toxicology.